New actions set out today position the UK as the most advanced genomic healthcare system in the world, and will create jobs.
Patients across the UK will benefit from better healthcare, treatments and faster diagnosis as the government sets out how it will continue to deliver world-leading genomic healthcare.
Genomics is the study of genetic information and can help diagnose diseases earlier and more accurately, reduce some invasive procedures and enable tailored treatments. Building on the success of the 100,000 Genomes Project, our commitment is to sequence 1 million whole genomes – 500,000 genomes in the NHS and 500,000 in UK Biobank, which will transform healthcare in the UK and create jobs. In 2018 to 2019, genomics contributed £1.9 billion to our economy.
The UK’s continued international leadership makes it an attractive location for private-sector investment, helping drive the country’s economic recovery as we look to build back better, and deliver the government’s ambition of becoming a global life sciences hub.
Working with key partners across the genomics community, the bold new Genome UK implementation plan 2021 to 2022 published today sets out 27 commitments to deliver over the next year including 5 high-priority actions:
- Faster diagnosis and treatment of cancer using genomics through partnership working between Genomics England and NHS England/Improvement to identify technologies that could be used to enable faster and more comprehensive genomic testing for cancer.
- Whole genome sequencing for patients with rare diseases and cancer as part of the NHS Genomic Medicine Service. This builds on the success of the 100,000 Genomes Project, making the NHS the only healthcare system worldwide to routinely offer this life-changing test for earlier diagnosis.
- Engage closely with different communities to ensure diverse datasets, through bespoke screening programmes. This will ensure everyone across the UK can benefit from genomic healthcare and our genomic databases are representative of our diverse population. This is essential for equitable access to new techniques, such as polygenic risk scores (PRS) which compares a person’s risk to others with a different genetic makeup, and pharmacogenomics, which examines the role of the genome in the body’s response to drugs.
- Our Future Health, the UK’s largest-ever research programme, will begin recruiting up to 5 million people representative of the UK population, to collect and link multiple sources of health information, helping researchers to discover new ways to detect and prevent the development of diseases. This was originally established as the Accelerating Detection of Disease challenge through £79 million of UK Research and Innovation (UKRI) funding.
- Develop global standards and policies for sharing genomic and related health data. The National Institute for Health Research, Medical Research Council and Wellcome Trust will, over the next 5 years, provide a total of £4.5 million of funding to the Global Alliance for Genomics and Health, ensuring standards are easily accessible and usable by global genomic programmes and data-sharing initiatives, placing the UK at the forefront of secure sharing of international genomic and health-related data.
Speaking in the House of Commons today, the Health and Social Care Secretary Matt Hancock said:
Minister for Innovation Lord Bethell said:
This first phase implementation plan follows on from Genome UK: the future of healthcare published in 2020, which set out a vision to create the most advanced genomic healthcare system in the world, to deliver better healthcare at lower cost.
The plan contains ambitious England-specific and UK-wide commitments, reflecting the devolved nature of healthcare while highlighting our strengths when we work together – for example, the world-leading COVID-19 genome sequencing consortium, COG-UK.
Genomics is just one example of this government’s commitment to driving forwards health innovation in the UK, which will be central to our future health resilience, the growth of our world-leading life sciences sector and improving patient care.
These commitments are important first steps to realising Genome UK’s vision and ensuring everyone in the UK will benefit from genomics, by having access to predictive, preventative, and personalised healthcare.
Chris Wigley, Genomics England CEO, said:
Professor Dame Sue Hill, NHS England Chief Scientific Officer, said:
Welsh Government Health and Social Services Minister Eluned Morgan added:
Read more by clicking here.